4.99
1.48%
-0.075
SOPHiA Genetics SA stock is currently priced at $4.99, with a 24-hour trading volume of 108.26K.
It has seen a -1.48% decreased in the last 24 hours and a -2.16% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.96 pivot point. If it approaches the $5.34 resistance level, significant changes may occur.
Previous Close:
$5.065
Open:
$5.1
24h Volume:
108.26K
Market Cap:
$326.22M
Revenue:
$62.37M
Net Income/Loss:
$-78.98M
P/E Ratio:
-4.0902
EPS:
-1.22
Net Cash Flow:
$-57.80M
1W Performance:
+5.50%
1M Performance:
-2.16%
6M Performance:
+24.13%
1Y Performance:
+8.24%
SOPHiA Genetics SA Stock (SOPH) Company Profile
Name
SOPHiA Genetics SA
Sector
Industry
Phone
41 21 694 10 60
Address
Rue du Centre 172, Saint-Sulpice
SOPHiA Genetics SA Stock (SOPH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-03-23 | Initiated | BTIG Research | Buy |
Nov-23-22 | Initiated | Credit Suisse | Neutral |
Oct-15-21 | Resumed | Cowen | Outperform |
Aug-17-21 | Initiated | Cowen | Outperform |
Aug-17-21 | Initiated | Credit Suisse | Outperform |
Aug-17-21 | Initiated | JP Morgan | Overweight |
Aug-17-21 | Initiated | Morgan Stanley | Overweight |
View All
SOPHiA Genetics SA Stock (SOPH) Latest News
Principal Financial Group Inc. Raises Stake in SOPHiA GENETICS SA (NASDAQ:SOPH) - Defense World
Defense World
SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug ... - Financial Times
Financial Times
SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug ... - Marketscreener.com
Marketscreener.com
2024-05-30 | NDAQ:SOPH | Press Release | SOPHiA GENETICS SA - Stockhouse Publishing
Stockhouse Publishing
SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug ... - Financial Times
Financial Times
SOPHiA Genetics SA: Navigating Market Fluctuations with a 336.05M Market Cap - The InvestChronicle
The InvestChronicle
SOPHiA Genetics SA Stock (SOPH) Financials Data
SOPHiA Genetics SA (SOPH) Revenue 2024
SOPH reported a revenue (TTM) of $62.37 million for the quarter ending December 31, 2023, a +31.14% rise year-over-year.
SOPHiA Genetics SA (SOPH) Net Income 2024
SOPH net income (TTM) was -$78.98 million for the quarter ending December 31, 2023, a +9.68% increase year-over-year.
SOPHiA Genetics SA (SOPH) Cash Flow 2024
SOPH recorded a free cash flow (TTM) of -$57.80 million for the quarter ending December 31, 2023, a +28.17% increase year-over-year.
SOPHiA Genetics SA (SOPH) Earnings per Share 2024
SOPH earnings per share (TTM) was -$1.22 for the quarter ending December 31, 2023, a +10.95% growth year-over-year.
About SOPHiA Genetics SA
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Cap:
|
Volume (24h):